ClinicalTrials.gg
Enrolling by invitationNCT05317429GlyCarbUpdated Jul 24, 2025

Glycaemic Responses to Carbohydrate-rich Meals (GlyCarb)

An interventional study of A meal delivering 75 g of carbohydrate in Glycaemia, sponsored by Quadram Institute Bioscience. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Quadram Institute Bioscience · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Carbohydrate-rich foods such as potatoes, bread, rice, pasta, breakfast cereals, biscuits and other snacks are a major component of the human diet. The effect of different carbohydrate-rich foods on blood sugar (glucose) levels after a meal varies between foods. This is relevant to health because studies have shown that regular intake of carbohydrate foods that cause large increases in blood glucose levels after ingestion can be detrimental to metabolic health.

The aim of the GlyCarb study is to investigate how food structure influences postprandial glycaemic responses to carbohydrate foods.

This will be achieved through a series of acute postprandial studies (up to 5 studies), wherein healthy participants within each postprandial study consume a pair of carbohydrate-rich test meals while wearing a continuous glucose monitoring system (CGM).

Each postprandial study will use the same GlyCarb Remote standard protocol, where a randomised cross-over design is used to measure the glycaemic response to two carbohydrate-rich test meals, one "test" and one "control". Both meals will be matched by carbohydrate content, contain similar ingredients and have a similar physical appearance, but will differ in one key food property (e.g., altered food structure) to test its effect on postprandial glycaemia.

In each postprandial study, habitual dietary intake and body composition will be captured at baseline as part of the participant characterisation. Participants will consume two different carbohydrate-rich test meals twice, on separate occasions, in a randomly allocated order over a 10 to 14-day period of continuous glucose monitoring. Data from the continuous glucose monitors will be used to assess the postprandial glycaemic response to each carbohydrate food. The participants will be required to complete brief questionnaires designed to evaluate differences in palatability (taste, texture, portion size) and satiety amongst test meals. Study participant feedback will be requested at the end of the study and used to assess and improve future study procedures.

The GlyCarb study will enable new understanding of how food properties influence glycaemic responses to different types of carbohydrate foods. Ultimately, the findings will inform the rational design or reformulation of food products and diets to support a healthy glucose metabolism.

Read the detailed description

The overarching aim of this project is to investigate a wide range of carbohydrate rich test meals (from 'off the shelf' commercially available products, through to enriched, restructured and re-formulated food products) on postprandial glycaemic response in normo-glycaemic individuals.

The 'remote' study protocol has been designed to maintain social distancing and thereby reduce risk of COVID19 transmission between participants and researchers during the ongoing outbreak. It also makes excellent use of continuous glucose monitoring devices, which enable continuous recording of participant body sugar levels in 'free-living' conditions. At no point will the participant be required to attend a clinical research facility. Support from the study team to participants will be provided through virtual appointments.

The study population will be healthy participants. Participants will also need to have access to a smart phone to be used in conjunction with the CGM as well as for virtual study appointments (video call) and to complete online forms.

The precise test meals will vary from study to study, and will always need to meet a set standard with regard to microbiological safety, traceability and nutrient composition. As an extra precaution, participants with ANY food allergy will not be able to take part in the study. The meals will be well characterised and details of nutrient composition, ingredients, allergens etc. will be provided to participants prior to consent.

Informed consent - to ensure participants can make an informed decision as to whether or not they wish to take part on the trial they will be provided with a study specific PIS and invited to participate in an informal discussion about the study. Consent will be obtained by a member of staff who is GCP trained and experienced in conducting human intervention trials. In line with the 'remote' nature of the study, participants and study team members will be video and audio recorded during the consent procedure, with their permission. Hard copies of the consent form will also be initialled and signed by the participant and countersigned by the study team as written informed consent.

Risks/Burdens - (i) At the eligibility assessment a small blood sample is collected. Participants may feel a little discomfort on initial insertion of the needle or bruising at the site of venepuncture. Similarly, there may be some discomfort during finger prick testing. (ii) The CGM sensor may be secured by an adhesive 'plaster' which could cause irritation. Should this occur the CGM could be secured in place with an elastic support bandage such as tubigrip or similar.

iii) This study involves periods of fasting. Participants will be advised to drink water during the fasting period. All study sessions will be scheduled for the morning time to reduce the length of fast.

(iv) As part of the eligibility assessment it is possible that some test results are returned as abnormal. Abnormal blood and urine test results are reviewed by our medical doctor who advises whether inclusion, re-screen or exclusion is appropriate. In addition, copies of all test results (whether abnormal or not) will be sent to the participants GP.

Participants will complete a Food Frequency Questionnaire to capture the habitual diet as a baseline characteristic as well as measure fat and muscle mass using a smart scale.

Data protection and confidentiality - Participants will be assigned a unique code and a Quadram Institute Bioscience (QIB)-based email which will be used on all samples/data arising from a study. Paper documents containing identifiable information (e.g. consent forms) and coded information will be kept in locked cabinets at the QIB. The file linking the code with the participant will be kept separately. All documents will only be accessible to the members of the study team. All electronic data will be stored on a password protected shared file at the QIB and access will be limited to members of the study team.

02

Conditions studied

  • Glycaemia

Keywords

  • Carbohydrates
  • Starch
03

In context

Lead sponsor

Quadram Institute Bioscience is the lead sponsor of 44 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age
  • Have access to/own a smartphone or tablet or computer and are willing to use this with apps needed for the study
  • between 18 and 30 kg/m2 (calculated from self-reported height and weight)
  • Fasted \< 42 mmol/mol (6.0%)
  • Willing to consume study foods (study foods and ingredients are discussed during the study talk)

Exclusion criteria

Exclusion Criteria:

  • Smokers of tobacco-based cigarettes or electronic cigarettes (or stopped smoking less than 6 months ago)
  • Gastro-intestinal disease/disorders e.g., Crohn's disease/ulcerative colitis
  • Other medical conditions that are judged to affect the study outcome or which may compromise the well-being of the participant e.g., active cancer, haemophilia. This will be assessed on a case-by-case basis.
  • Type 1 diabetes or insulin-dependent or non-insulin-dependent type 2 diabetes
  • Active infection with COVID-19, unless they are willing to postpone the screening until after the end of the self-isolation period (10 days from test or symptoms).
  • Prescribed and non-prescribed medications that may affect the study outcome or which may compromise the well-being of the participant e.g., warfarin, proton-pump inhibitors. This will be assessed on a case by-case-basis.
  • Dietary supplements that are judged to affect the study outcome unless the participant is willing to discontinue them for 4 weeks preceding the start of the study and for the duration of the study. This will be assessed on a case-by-case basis and includes protein supplements (shakes) or supplements that are not taken on a regular basis (on and off), particularly those containing ascorbic acid which may affect glucose readings.
  • Any known allergy, intolerance, or sensitivity to any food products oradhesives (for CGM application).
  • Those following a restrictive diet that may affect the study outcome (e.g., 5:2 diet) unless they are willing to suspend the diet for the duration of the study.
  • Women who are, or have been pregnant, within the last 12 months or who are breast-feeding
  • Parallel participation in another research project that involves dietary intervention.
  • Any person related to or living with any member of the study team.
  • Those who are part of the line manager/supervisory team of the Chief Investigator
  • Lack of capacity to provide written .
  • Clinical eligibility test results deemed by the CRF medical advisor to be indicative of a health problem which may compromise the well-being of the participant or which could affect the study outcome.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Treatment

    Carbohydrate-rich meal

    Other: A meal delivering 75 g of carbohydrate

  • Active comparator
    Control

    Carbohydrate-rich meal

    Other: A meal delivering 75 g of carbohydrate

Interventions

  • OtherA meal delivering 75 g of carbohydrate

    The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following: (i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity.

06

What researchers measure

Primary outcomes

  1. Fasting and postprandial glucose levels measured in interstitial fluid

    Maximum rise in glucose concentration from fasted levels (iCmax)

    Time frame: 0-4 hours after the test meal

Secondary outcomes

  1. Glycaemic response indicators

    Incremental area under the curve (iAUC) for the first peak

    Time frame: 2 to 4 hours after the test meal

  2. Glycaemic response indicators

    Incremental area under the curve (iAUC) between 0-120 min

    Time frame: 2 to 4 hours after the test meal

  3. Glycaemic response indicators

    Minimum glucose concentration (Cmin)

    Time frame: 2 to 4 hours after the test meal

  4. Glycaemic response indicators

    Time to reach glucose peak concentration (Tmax), time to reach minimum concentration (Tmin)

    Time frame: 2 to 4 hours after the test meal

  5. Glycaemic response indicators

    Time to reach minimum glucose concentration (Tmin)

    Time frame: 2 to 4 hours after the test meal

  6. Glycaemic response indicators

    Coefficient of variation (CV)

    Time frame: Over 14 days

  7. Glycaemic response indicators

    Time in Range (TIR)

    Time frame: Over 14 days

  8. Glycaemic response indicators

    Mean Amplitude Glucose Excursion (MAGE)

    Time frame: Over 14 days

  9. Glycaemic response indicators

    Mean of daily differences (MODD)

    Time frame: Over 14 days

  10. Satiety

    Online survey responses from participants.

    Time frame: Time 0 (before meal), 30 (after meal), 60, 120, 180 and 240 minutes after each test meal.

  11. Palatability

    Online survey responses from participants. Palatability scores (recorded once after each test meal), from 'Dislike Very Much' to 'Like Very Much'.

    Time frame: Once per day on intervention days, four times per study

Other outcomes

  1. BMI

    weight and height will be combined to report BMI in kg/m\^2

    Time frame: Baseline

  2. Body composition

    Percentage of fat mass

    Time frame: Baseline

  3. Body composition

    Percentage of muscle mass

    Time frame: Baseline

  4. Habitual dietary Intake

    Food Frequency Questionnaire

    Time frame: Baseline

07

Study locations

1 site
  • Quadram Institute
    Norwich, Norfolk NR4 7UQ, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data for primary and secondary outcome measures will be made available

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will be available after publication in scientific journal within 18 months of study completion

Access criteria: Data access will be reviewed by the study team

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Mar 2028, 73 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Apr 7, 2022
StartActual
Feb 14, 2022
Primary completionEst.
Mar 31, 2028
CompletionEst.
Jun 30, 2028
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05317429
Lead sponsor
Quadram Institute Bioscience
Collaborators
Norfolk and Norwich University Hospitals NHS Foundation Trust
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
Feb 14, 2022
Primary completion
Mar 31, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Jul 24, 2025

Study contacts

Cathrina Edwards, PhD
principal investigator · Quadram Institute Bioscience

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion